<DOC>
	<DOCNO>NCT02307487</DOCNO>
	<brief_summary>A prospective , open label , modify 3+3 dose escalation study . This dose-escalation study design carefully assess safety successive cohort patient ( 3 patients/cohort ) , cohort treat fix dose TC-3 MMC Intravesical instillation .</brief_summary>
	<brief_title>Safety Pre-TURBT Intravesical Instillation Escalating Doses TC-3 Gel MMC NMIBC Patients</brief_title>
	<detailed_description>A prospective , open label , modify 3+3 dose escalation study . This dose-escalation study design carefully assess safety successive cohort patient . A total 10 patient treat first cohort 120mg MMC-TC-3 Gel unless DLT reach 1/3 patient cohort . The next cohort 3 patients/cohort , cohort treat fix dose TC-3 MMC Intravesical instillation . Since data already available 40 80 mg MMC TC-3 gel , initial cohort 120mg MMC mix 60 mL TC-3 . Subsequent cohort give dose level 140mg &amp; 160mg MMC mix 60 mL TC-3 . Thus , 160mg MMC mixed 60ml TC-3 find safe tolerable , high dos explore stage . If 120 mg MMC 60 ml TC-gel ( 2 mg/ml ) find intolerable , high concentration test . Instead , dose 120 mg 90 cc TC gel subsequent dose 140 160 mg MMC 90 cc TC gel test dose escalate manner . This allow test similar dos low concentration ( 1.78 mg/ml ) long dwell time due large volume TC-gel . Dose escalation halt maximum tolerate dose ( MTD ) reach ; MTD define one dose level dose limited toxicity ( DLT ) Any adverse event ( AE ) relate TC-3+MMC qualify per National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) grade 3 4 evaluate board 2 independent physician determine qualifies DLT base know safety profile MMC . If NCI grade apply , adverse event grade mild , moderate , severe . If one three patient cohort experienced DLT , three patient add cohort AE confirmation , 3 patient give cohort experience DLT , MTD reach If DLTs observe cohort , three patient enrol next successive cohort .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Diseases</mesh_term>
	<mesh_term>Urologic Diseases</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>Patient 18 year age old . Patient sign Informed Consent Form willing able abide protocol . Patients diagnose Low Grade ( LG ) High grade ( HG ) NMIBC . No active urinary tract infection confirm urine culture . If patient female childbearing potential , use two acceptable &amp; effective method contraception , 6 month post treatment A negative serum pregnancy test screen female patient childbearing potential If patient male use condom intercourse , least 48 hour post instillation . If patient male partner female childbearing potential , advise use two acceptable &amp; effective method contraception 6 month post treatment . Tumor locate prostatic urethra ( male patient ) bladder diverticulum . Prior require pelvic radiotherapy . Systemic chemotherapy within 1 year prior screen . Pregnant breastfeed female patient . Treatment bladder cancer BCG within last 12 month prior screen visit . Exception : For patient BCG treatment within 612 month prior screen visit symptomatic , patient may enroll investigator discretion . Treatment ( full course ) intravesical chemotherapy within 3 month , prior screen visit . Contraindication MMC treatment per investigator determination , know sensitivity MMC TC3 ingredient . The patient know current urinary retention require intermittent catheterization empty bladder . The patient bleed disorder screen platelet count &lt; 100X109/L . The patient screen hemoglobin &lt; 10g/dL OR white blood cell &lt; 4000 mm3 . GFR &lt; 30 Hepatic value exceed 2 time upper normal limit . The patient concurrent severe and/or uncontrolled medical condition ( e.g. , uncontrolled diabetes , compensate congestive heart failure [ NYHA III ] , myocardial infarction within 6 month screen visit , unstable uncontrolled hypertension active uncontrolled infection ) psychiatric disease , could compromise participation , compliance schedule visit , and/or completion study opinion investigator . The patient document severe vesicoureteral reflux indwell ureteral stent . The patient participate investigational interventional study within past 90 day , prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>TC-3 Gel</keyword>
	<keyword>MMC</keyword>
	<keyword>NMIBC</keyword>
	<keyword>Non Muscle Invasive Bladder Cancer</keyword>
	<keyword>Hydrogel Reverse thermal gelation</keyword>
	<keyword>Drug retention</keyword>
	<keyword>Urinary Bladder Neoplasms</keyword>
	<keyword>Urologic Neoplasms</keyword>
	<keyword>Urinary Bladder Diseases</keyword>
	<keyword>Urologic Diseases</keyword>
</DOC>